Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung …

ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer

TRIANA Biomedicines, Inc.NCT07491497